en.Wedoany.com Reported - Azurity Pharmaceuticals, Inc., a company dedicated to providing innovative pharmaceutical solutions for specific patient populations, announced that its developed ARYNTA™ (lisdexamfetamine dimesylate) oral solution (CII) is now officially available in the United States. This medication is primarily intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older, including adults, offering a new, more flexible and convenient option for clinical treatment.
ARYNTA™ is a ready-to-use lisdexamfetamine oral solution, with its key technical advantage being stable storage at room temperature of 20°C to 25°C (68°F to 77°F), requiring no refrigeration. The drug received approval from the U.S. Food and Drug Administration (FDA) in June 2025. As a prodrug of amphetamine, this oral solution demonstrated significant efficacy in pivotal Phase 3 clinical trials, effectively alleviating core symptoms such as hyperactivity, impulsivity, and inattention. Pharmacokinetic data indicate that its effect can last up to 13 hours in children and 14 hours in adults, with a safety and tolerability profile similar to other stimulant medications.
Azurity Pharmaceuticals CEO Ronald Scarboro emphasized that providing this innovative oral solution aims to address the needs of patients overlooked by traditional dosage forms. Statistical data show that approximately 70% of children and 30% of adolescents have difficulty swallowing tablets or capsules. Furthermore, about 40% of children with autism also have ADHD, and these children are often extremely sensitive to the texture of food or medication. The liquid form of ARYNTA™, which requires no capsules or sprinkling, can effectively alleviate medication challenges for such special populations.
Currently, ARYNTA™ is available through major pharmacy chains across the United States. Azurity officials remind that this medication is a controlled substance (CII) and carries a black box warning regarding risks of abuse and dependence. Patients and healthcare professionals can visit the official website for detailed prescribing information and safety instructions. This launch marks another significant breakthrough in innovation for drug delivery systems within the global ADHD treatment field.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
